Scios, Inc. clinical trials

Acquired by Johnson & Johnson, Apr 29, 2003 · source ↗

The registry lists 22 studies whose lead sponsor is Scios, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 20, 2016.

Studies

Recruiting first, then most recently updated. Showing 22 of 22. All Johnson & Johnson studies →

• An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)WithdrawnNCT00530361Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMACTerminatedNCT00338455Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Heart Failure RegistryCompletedNCT00530426

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.CompletedNCT00113893Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart FailureCompletedNCT00475852Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care TherapyCompletedNCT00270387Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.CompletedNCT00270361Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.CompletedNCT00270374Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at RestCompletedNCT00288730Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart FailureCompletedNCT00270400Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart FailureCompletedNCT00091520Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid ArthritisCompletedNCT00508768Phase 1

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSSCompletedNCT00652652Phase 4

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPACompletedNCT00653042Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood VesselsCompletedNCT00271557Phase 3

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00095680Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple MyelomaCompletedNCT00087867Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving MethotrexateCompletedNCT00089921Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Registry for Acute Decompensated Heart Failure Patients Admitted to the ERCompletedNCT00364325

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Longitudinal Registry for Advanced Heart Failure PatientsCompletedNCT00364416

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson

• Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving MethotrexateCompletedNCT00043732Phase 2

  Sponsor listed in the registry: Scios, Inc. · First submitted before Scios, Inc. became part of Johnson & Johnson

• Registry for Acute Decompensated Heart Failure PatientsCompletedNCT00366639

  Sponsor listed in the registry: Scios, Inc. · First submitted after Scios, Inc. became part of Johnson & Johnson